Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of BJ 005 in China

Trial Profile

A clinical trial of BJ 005 in China

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BJ 005 (Primary)
  • Indications Cancer
  • Focus Adverse reactions

Most Recent Events

  • 18 Oct 2019 New trial record
  • 11 Oct 2019 According to a CMAB Biopharma media release, CMAB Biopharma and BJ Bioscience Establish an Exclusive Strategic Partnership.Under this agreement, CMAB will provide a full range of CMC research and manufacturing services that meet the IND application requirements of both China and the United States. The strategic cooperation will support the clinical development of BJ-005 worldwide by BJ Bioscience and is based upon CMAB's award-winning CMC process development and manufacturing platform.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top